4.4 Article

The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation

期刊

GLOBAL HEART
卷 12, 期 4, 页码 273-284

出版社

UBIQUITY PRESS LTD
DOI: 10.1016/j.gheart.2017.01.015

关键词

-

资金

  1. 3M
  2. Biosense
  3. BMS/Pfizer
  4. Boehringer Ingelheim
  5. Sanofi-Aventis
  6. St. Jude
  7. Deutsches Zentrum fur Herz-Kreislaufforschung (DZHK)
  8. Federal Ministry for Education and Research
  9. Bayer Pharma AG
  10. AstraZeneca
  11. Gilead
  12. Servier
  13. Bayer AG Health-Care
  14. Janssen
  15. Johnson Johnson
  16. Medtronic
  17. Ortho-McNeil-Janssen Pharmaceuticals
  18. BMS
  19. Bayer
  20. Pfizer

向作者/读者索取更多资源

Background: The World Heart Federation has undertaken an initiative to develop a series of Roadmaps to promote development of national policies and health systems approaches, and to identify potential roadblocks on the road to effective prevention, detection, and management of cardiovascular disease in low- and middle-income countries (LMICs) and develop strategies for overcoming these. This Roadmap focuses on atrial fibrillation (AF). AF is the most common, clinically significant arrhythmia and, among other clinical outcomes, is associated with increased risk of stroke. Methods: Development of this Roadmap included a review of published guidelines and research papers, and consultation with an expert committee comprising experts in clinical management of AF and health systems research in LMICs. The Roadmap identifies 1) key interventions for detection, diagnosis, and management of AF; 2) gaps in implementation of these interventions (knowledge-practice gaps); 3) health system roadblocks to implementation of AF interventions in LMICs; and 4) potential strategies for overcoming these. Results: More research is needed on determinants and primary prevention of AF. Knowledge-practice gaps for detection, diagnosis, and management of AF are present worldwide, but may be more prominent in LMICs. Potential barriers to implementation of AF interventions include long distances to health facilities, shortage of health care professionals with training in AF, including interpretation of ECG, unaffordability of oral anticoagulants for patient households, reluctance on the part of physicians to initiate oral anticoagulant (OAC) therapy, and lack of awareness of the importance of persistent adherence to OAC therapy. Potential solutions include training of nonphysician health workers and pharmacists in pulse-taking, use of telemedicine technologies to transmit electrocardiogram results, engagement of nonphysician health workers in OAC therapy adherence support, and country-specific support and education programs for noncardiologist health care professionals. Conclusions: AF affects millions of people worldwide and, left untreated, increases the risk and severity of stroke and heart failure. Although guidelines for the detection, diagnosis, and management of AF exist, there are gaps in implementation of these guidelines globally, and in particular in LMICs. This Roadmap identifies some potential solutions that may improve AF outcomes in LMICs but require further evaluation in these settings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据